Carfilzomib/Daratumumab/Dexamethasone Regimen

Preferred Label : Carfilzomib/Daratumumab/Dexamethasone Regimen;

NCIt synonyms : Daratumumab-KD Regimen; Carfilzomib/Daratumumab/Dexamethasone; Carfilzomib/Dexamethasone/Daratumumab; Carfilzomib-Daratumumab-Dexamethasone; Carfilzomib-Dexamethasone-Daratumumab; Daratumumab Plus KD Regimen; Carfilzomib-Daratumumab-Dexamethasone Regimen; Darzalex-KD Regimen; Carfilzomib-Dexamethasone Plus Daratumumab; Carfilzomib/Dexamethasone Plus Daratumumab; Kyprolis/Dexamethasone/Darzalex;

NCIt related terms : Dara-Kd (SC daratumumab); Dara-Kd;

NCIt definition : A regimen consisting of carfilzomib, daratumumab and dexamethasone that can be used for the treatment of relapsed or refractory plasma cell (multiple) myeloma.;

NCI Metathesaurus CUI : CL1664473;

Codes from synonyms : 28460; 6547;

Details

Origin ID

C181590;

UMLS CUI

C5557172;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Carfilzomib [NCIt concept]
- Daratumumab [NCIt concept]
- Dexamethasone [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients